OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Ansell on Promising Combinations Being Studied in MCL

May 17th 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses promising combinations in the pipeline for mantle cell lymphoma (MCL).

Dr. Black on Combinations with Durvalumab in Bladder Cancer

May 17th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Center, associate professor, Department of Urologic Sciences, University of British Columbia, discusses combination trials with durvalumab (Imfinzi) for patients with bladder cancer.

Dr. Gupta on VEGF Inhibitors Combined with Immunotherapy in Kidney Cancer

May 17th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses combining VEGF inhibitors with immunotherapy for patients with kidney cancer.

Dr. Begna on Recent Advancements in MPNs

May 16th 2017

Kebede H. Begna, MD, assistant professor of Medicine, Mayo Clinic, discusses some of the recent advancements in the field of myeloproliferative neoplasms (MPNs).

Dr. Nowakowski on Next Steps With Emerging Agents in MCL

May 16th 2017

Grzegorz S. Nowakowski, MD, an assistant professor of Medicine at Mayo Clinic, discusses the status of emerging agents moving through the pipeline of mantle cell lymphoma.

Dr. Strosberg Discusses Trials in Neuroendocrine Tumors

May 16th 2017

Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses trials in neuroendocrine tumors (NETs).

Dr. O'Regan Discusses the Future of Treatment in HER2+ Breast Cancer

May 16th 2017

Ruth O’Regan, MD, division head of Hematology and Oncology in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, discusses the potential of future treatments for patients with HER2-positive breast cancer.

Dr. Campbell on the Guidelines for the Management of Kidney Cancer

May 16th 2017

Steven Campbell, MD, PhD, urologist, Cleveland Clinic, discusses the recent guidelines for the management of patients with kidney cancer.

Dr. Bratslavsky on the Evaluation and Management of Kidney Cancer

May 16th 2017

Gennedy Bratslavsky, MD, deputy director of Upstate Cancer Center, director of the Robotic Program for all Upstate Campuses, and director of the VHL Clinical Cancer Center, discusses the evaluation and management of kidney cancer.

Dr. Raman on Hematuria in Urothelial Cancer

May 16th 2017

Jay D. Raman, MD, professor of Surgery and chief of the Division of Urology at Penn State Milton S. Hershey Medical Center, discusses hematuria in patients with urothelial carcinoma.

Dr. Stephenson on the Quality of Life Following the Management of Localized Prostate Cancer

May 16th 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic discusses urinary, bowel, and sexual function following the management of localized prostate cancer.

Dr. Corn on Possibility of Immunotherapy for Patients With Prostate Cancer

May 15th 2017

Paul G. Corn, MD, PhD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the possibility of immunotherapy in patients with prostate cancer.

Dr. Leonard on Rituximab Maintenance Strategy for Patients With MCL

May 15th 2017

John P. Leonard, MD, professor of medicine at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the maintenance strategy of rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).

Dr. Loeb on Active Surveillance for Prostate Cancer

May 13th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses active surveillance for patients with low-risk prostate cancer.

Dr. Hu on the Increase in Incidence of Advanced Prostate Cancer

May 13th 2017

Jim C. Hu, MD, professor of Urology, Weill Cornell Medical College, discusses the increase in the incidence of advanced prostate cancer in the United States.

Dr. Furman on Utility of Prognostic Markers in CLL

May 12th 2017

Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the use of prognostic markers in the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Govindan on the Future of EGFR-Mutant NSCLC

May 11th 2017

Ramaswamy Govindan, MD, professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the future treatment landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Morgensztern on Impact of Immunotherapy on NSCLC Field

May 11th 2017

Daniel Morgensztern, MD, associate professor, Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in St. Louis, discusses the monumental impact that immunotherapy has had on the field of non–small cell lung cancer (NSCLC).

Dr. Devarakonda on Biomarkers Beyond PD-L1 in NSCLC

May 11th 2017

Siddhartha Devarakonda, MD, a senior fellow at Washington University School of Medicine in St. Louis, discusses biomarkers beyond PD-L1 being explored in patients with non–small cell lung cancer (NSCLC).

Dr. McDermott on the Role of VEGF Targeted Therapy in RCC

May 11th 2017

David F. McDermott, MD, director, Biologic Therapy and Cutaneous Oncology Programs, Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the role of VEGF-targeted therapy in renal cell carcinoma.